GLP-1 and Vision Loss: NAION Risk With Ozempic, Wegovy & Mounjaro 2026

The headline finding

In July 2024, a Harvard Medical School study in JAMA Ophthalmology made international news: patients prescribed semaglutide had a significantly higher rate of NAION — non-arteritic anterior ischemic optic neuropathy — a sudden, painless loss of vision caused by reduced blood flow to the optic nerve. Diabetic semaglutide users showed roughly 4x the risk; overweight/obese users roughly 7x the risk compared to matched non-users.

Subsequent larger studies through 2025-2026 painted a more nuanced picture: the association appears real but smaller than the initial estimate — most analyses now suggest roughly 1-3 additional NAION cases per 10,000 patient-years of GLP-1 use. Rare, but serious when it happens: NAION vision loss is usually permanent.

What NAION actually is

NAION is sometimes called a "stroke of the optic nerve." Blood flow to the front of the optic nerve drops suddenly, damaging the nerve fibers that carry vision. Patients typically wake with blurred, dim, or partially missing vision in one eye — no pain, no warning. Vision may partially recover over months, but most patients are left with some permanent deficit.

The proposed GLP-1 mechanism isn't proven. Leading theories: rapid blood glucose reduction alters optic nerve perfusion (similar to the known "early worsening" of diabetic retinopathy when glucose drops fast), or GLP-1's effects on blood pressure and vascular tone affect an already-vulnerable optic disc.

Who is actually at elevated risk

Warning signs — act immediately

• Sudden painless vision loss in one eye, often on waking
• A dark or gray area in part of your visual field
• Colors looking washed out or dim in one eye
• Any sudden vision change on GLP-1 — don't wait

If any of these occur: stop the medication and get an emergency ophthalmology evaluation. NAION is diagnosed on exam; early documentation matters for both treatment decisions and any future prescribing choices.

What regulators and labels say in 2026

The EMA reviewed the NAION signal and concluded semaglutide labels should list NAION as a very rare potential side effect. The FDA has monitored the signal without a formal label change as of late 2026, though prescribing information continues to evolve. Novo Nordisk maintains the benefit-risk profile remains favorable — which is broadly true at population level, but doesn't eliminate individual risk for high-risk patients.

The practical protocol

1. Baseline eye exam before starting — especially with diabetes, hypertension, or sleep apnea. Ask specifically about optic disc appearance ("crowded disc" = higher NAION susceptibility).
2. Diabetics with retinopathy: ophthalmology clearance first. Rapid A1c drops can worsen retinopathy independent of NAION.
3. Report vision changes immediately — same day, not next appointment.
4. Prior NAION = avoid GLP-1s — the consensus position for protecting the remaining eye.

Related GLP-1 guides

• GLP-1 and Thyroid Cancer Risk
• GLP-1 and Pancreatitis
• GLP-1 and Gastroparesis
• GLP-1 and Surgery
• GLP-1 Heart Benefits
• GLP-1 and Kidney Health
• What Happens When You Stop GLP-1
• GLP-1 Complete Guide